Anjin's 19 billion yuan stake in Baiji Shenzhou will jointly develop 20 anti-tumor drugs in the future.

(Health Times reporter Zhao Mengmeng)
. Recently, Baiji Shenzhou and the global biopharmaceutical giant Anjin reached a global strategic partnership of oncology, Amjin spent $2.7 billion (about 19 billion yuan) to buy 20.5 percent of Baiji Shenzhou shares. Baiji Shenzhou, on the other hand, has been granted the right to develop and commercialize three of Amway's drugs in Chinese mainland, and will jointly develop 20 anti-tumor drugs with Amin globally in the future.
" After the news came out, I received a lot of doctors and experts wechat, we are very excited," said Wu Xiaobin, general manager and president of Baiji Shenzhou China, who knows that doctors come into contact with patients every day, they know the pain of not having good medicine, and doctors and patients are eager to innovate.Health Times reporter Xu Weizhao
the founder, chairman and chief executive officer of Baiji Shenzhou, chairman and chief executive officer, said that the cooperation between Baiji Shenzhou and Anjin is mainly two aspects, one is around Amgen's three approved mature tumor products Xgeva (dishumono), Kyprolis (Kafizomi) and dual antibody-specific drug Blincyto (Pirinto-) in China for commercialization for five years or seven years.
, XGEVA has been launched in China in 2019 for the non-surgical removal of osteoblastoma or surgical removal of adults and mature-grown adolescents with bone cytomegaloblastomas. The treatment of multiple myeloma carfizomi and the treatment of recurrent or refractable adult acute lymphoblastic leukemia perrinated by Perrintomo duonotated in China and are in the late stageof clinical development.
Is to develop more than 20 additional anti-tumor drugs in the research with Anjin, most of which are now in the early stages of development, and Baiji Shenzhou will be responsible for the clinical advancement of these drugs and commercialization in China. Baiji Shenzhou will receive its approval after seven years of commercialization rights. Small molecule-targeted drugs, including the first-in-class research in the KRAS G12C inhibitor AMG 510, as well as bispecific T-cell binding antibody (BiTE) immunotherapy.Wu Xiaobin, a
, stressed that the cooperation between Baiji Shenzhou and Anjin is by far the largest in the country and between Chinese biopharmaceutical companies, involving the largest number of products, and the first overseas pharmaceutical companies to China's biopharmaceutical companies equity cooperation. Whether from research, clinical development, production and commercialization, will build a new platform for patients in China.
.